Insurers Urge Court To Preserve Cancer Drug Antitrust Suit
By Julia Arciga · January 7, 2021, 4:44 PM EST
Four insurance companies fought back Wednesday against a Bristol-Myers Squibb unit's efforts to stamp out their antitrust lawsuit, claiming they suffered injuries after Celgene sold cancer medicines Thalomid and Revlimid at...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login